Danish drugmaker Novo Nordisk A/S offered to acquire obesity startup Metsera Inc. for at least $6.5 billion, seeking to trump an agreed deal with Pfizer Inc. so it can consolidate its position in weight-loss medications. Novo Nordisk submitted an unsolicited proposal to acquire Metsera for $56.50 per share in cash upfront, it said in a statement, confirming an earlier Bloomberg News report. The purchase price may increase by as much as $21.25 per share, or $2.5 billion, if certain targets are met. The swoop on Metsera is the latest move by Novo Nordisk, which under Chief Executive Officer Maziar Mike Doustdar is fighting to regain the company’s lead in weight-loss drugs.
Read the full article: Novo Nordisk Offers $6.5B for Metsera to Challenge Pfizer //
Source: https://finance.yahoo.com/news/novo-nordisk-offers-6-5-103104241.html